Kerenida is currently approved to slow the progression chronic kidney disease associated with type 2 diabetes.

Bayer (BAYZF) (BAYRY) says elinzanetant, its experimental therapy for hot flashes, reached the main goals in a late-stage ...

Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the ...

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Thursday, Bayer shared top-line data from a phase 3 trial that tested elinzanetant in women on adjuvant endocrine therapy for ...

(RTTNews) - Bayer Aktiengesellschaft (BAYRY.PK), Thursday announced that Elinzanetant, a non-hormonal drug, has met all primary and second endpoints in the Phase III study OASIS 4, investigating the ...

Bayer said its Elinzanetant drug, which targets some symptoms produced by endocrine therapy in women with breast cancer, met all primary and secondary endpoints in a study. The German pharmaceutical ...

Durham-based Tavros Therapeutics, a precision oncology company spun out of Duke University, has been acquired by a subsidiary of global life sciences titan Bayer AG. Financial terms of the deal with ...

The addition of Tavros greatly expands Vividion's functional genomics expertise and capabilities, bringing proprietary methods for genomic screening that can identify new target opportunities, as well ...

Whether ahead of their time, truly bizarre, or just plain doomed, it’s certainly interesting to see companies go completely ...

Changes are coming to the cold and cough aisle of your local pharmacy: U.S. officials are moving to phase out the leading decongestant found in hundreds of over-the-counter medicines, concluding that ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...